|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Hayat Pharmaceutical Industries Company (حياة للصناعات الدوائية)
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Hayat Pharmaceutical Industries Company (حياة للصناعات الدوائية) Headquarters Hayat Pharmaceutical Industries (HPI) P.O. Box 1564 Amman 11118 Jordan ; Amman; West Zone; 11118 |
Status: Listed Legal Form: Other non-liability limited Operational Status: Operational ISIN CODE : JO4121011012 Financial Auditors: Ghosheh and Company (2012) Total Employees: 173 Tel: 00962 6 4162607 |
|
Company Description |
| Hayat Pharmaceutical Industries (HPI) is a Jordan-based public shareholding company that specializes in the manufacture, import, export and marketing of general pharmaceutical products. The Company’s manufacturing facility is spread over an 8,000 square meter area on the outskirts of the capital city Amman. It includes three production lines: the solid dosage forms, such as tablets, capsules and dry suspensions; the semi-solid dosage forms, such as creams, ointments, suppositories, and gels, and | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the Year of 2011, total net operating revenues increased with 25.51%, from JOD 4,995.087 thousands to JOD 6,269.094 thousands. The results of the period increased 84.32% reaching JOD 923.323 thousands at the end of the period against JOD 500.937 thousands last year. Return on equity (Net income/Total equity) went from 4.56% to 8.24%, the Return On Asset (Net income / Total Asset) went from 4.13% to 7.37% and the Net Profit Margin (Net Income/Net Sales) went from 10.03% to 14.73% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 11.77% compared to 10.26% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 5.46 to 5.22 when compared to the previous year. |
Key Executives |
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2011 Y (non-cons) |
2010 Y (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| Finglobe - MENA Spread Financial Statements | Finglobe - MENA Spread Financial Statements | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
12,521 |
12,119 |
| ||
Current Assets |
6,882 |
6,159 |
| ||
Total Liabilities |
1,318 |
1,127 |
| ||
Shareholders Equity |
11,202 |
10,992 |
| ||
Current Liabilities |
1,318 |
1,127 |
| ||
| * All the accounts are in JOD. | ||
Income Statement
| ||
Total Operating Revenue |
6,269 |
4,995 |
| ||
Net Profit (Loss) |
923 |
500 |
| ||
| * All the accounts are in JOD. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
7.37% |
4.13% |
| ||
Annualised Return on Assets (ROA) |
7.37% |
4.13% |
| ||
Return on Equity (ROE) |
8.24% |
4.56% |
| ||
Annualised Return on Equity (ROE) |
8.4% |
4.47% |
| ||
Return on Sales (ROS) |
14.73% |
10.03% |
| ||
Gross Profit Margin |
131.11% |
134.14% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
1.04x |
1.39x |
| ||
Inventory Turnover |
3.50x |
4.57x |
| ||
Current asset turnover |
0.91x |
0.81x |
| ||
Fixed-asset turnover |
1.11x |
0.84x |
| ||
Asset Turnover |
0.50x |
0.41x |
| Valuation figures and ratios | ||
| ||
Enterprise value |
10,800 |
7,799 |
| ||
Bookvalue (BV) |
11,202 |
10,992 |
| ||
Net Cash |
-350 |
-769 |
| Liquidity Ratios | ||
| ||
Current Ratio |
521.97% |
546.28% |
| ||
Quick ratio |
386.09% |
449.3% |
| ||
Doom's day ratio |
73.43% |
31.73% |
| ||
Cash Flow to Debt |
129.27% |
54.77% |
| Leverage Ratios | ||
| ||
Leverage ratio |
111.77% |
110.26% |
| ||
Debt to equity |
11.77% |
10.26% |
| ||
Debt to total assets |
10.53% |
9.3% |
| Market ratios | ||
| ||
Market Cap / Net cash |
-29.83 |
-9.13 |
| Trend Ratios | ||
| ||
Revenue Trend |
125.51% |
105.29% |
| ||
Net Income Trend |
184.32% |
99.99% |
| ||
 |